In short
Clinical trials are investigating Azd5492 in adults with B-cell blood cancers. These studies aim to learn whether Azd5492 is safe and whether it may work alone or with other cancer treatments. The trial data shown here focuses on people with relapsed or refractory B-cell malignancies.
Key points
- Azd5492 is being studied in a Phase 1 trial in adults with B-cell blood cancers. The study is authorised and includes people with relapsed or refractory disease, meaning the cancer has returned or has not responded to earlier treatment. Researchers are looking at Azd5492 used alone and together with other cancer treatments. The main goals are to check safety, tolerability, and early signs of how well it may work. The trial also measures dose-limiting toxicities, side effects, serious side effects, vital signs, and lab test changes.
Trial overview
This authorised study is testing Azd5492 in adults with B-cell malignancies, which are cancers that start in B cells, a type of white blood cell. The trial title says the study is looking at whether Azd5492 is safe and whether it works when given alone and in combination with other cancer treatments.
The brief summary says the main objective is to assess the safety and tolerability of Azd5492 as monotherapy or in combination with other anticancer agents in participants with relapsed or refractory B-cell malignancies. Relapsed means the cancer came back after treatment, and refractory means it did not respond well to treatment.
Who can join
The study is for adults with B-cell blood cancers. The trial data also says participants have relapsed or refractory disease, so the cancer has either returned or has not improved enough after previous treatment.
No more detailed age, cancer subtype, or prior treatment rules are given in the trial data provided.
What is being measured
The main outcomes are focused on safety. Researchers will look for dose-limiting toxicities (DLTs), which are side effects serious enough to limit treatment, and they will also track the incidence and severity of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs).
The study will also check for SAEs or AEs that lead to stopping Azd5492, plus clinically significant changes in vital signs and abnormal laboratory parameters. Vital signs are basic body checks like blood pressure and pulse, while laboratory parameters are results from blood or other tests.
Trial phase and design
This is a Phase 1 study, which is an early clinical trial stage. Phase 1 studies mainly aim to understand safety and tolerability, and they may also give early clues about whether a treatment could help.
The study is listed as interventional, which means researchers are actively giving the treatment and observing the results. The enrollment number is 176, which is the planned number of participants in the study.
The intervention listed in the trial data is AZD5492 given by subcutaneous administration, which means under the skin.
What this means for patients
For patients, this trial is mainly about learning whether Azd5492 can be used safely in people with hard-to-treat B-cell blood cancers. The study is also exploring whether Azd5492 may be given by itself or together with other cancer treatments.
Because this is an early-phase study, the main focus is not yet on proving long-term benefit, but on understanding safety, side effects, and early treatment signals.